Phase I Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
Latest Information Update: 21 Feb 2025
At a glance
- Drugs VG 2025 (Primary)
- Indications Carcinoma; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- 07 Oct 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Apr 2024 New trial record